Immunic Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

New York City, New York 6,994 followers

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases

Discover all 84 employees

About us

Immunic (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Privacy Policy: https://imux.com/privacy-policy/

Industry

Biotechnology Research

Company size

51-200 employees

Headquarters

New York City, New York

Type

Public Company

Founded

2016

Locations

Employees at Immunic Therapeutics

Updates

📢 Publication Alert: 𝙏𝙝𝙚 𝙇𝙖𝙣𝙘𝙚𝙩 𝙂𝙖𝙨𝙩𝙧𝙤𝙚𝙣𝙩𝙚𝙧𝙤𝙡𝙤𝙜𝙮 & 𝙃𝙚𝙥𝙖𝙩𝙤𝙡𝙤𝙜𝙮! Dr. Andreas Muehler, Immunic’s Chief Medical Officer, shared insights on our phase 1/1b clinical trial results with Proactive’s Stephen Gunnion, underscoring the significance of this data set and its publication in such a prestigious journal. ▶ https://bit.ly/3UQ4pYwIMU-856 has shown promising potential as a once-daily oral treatment for celiac disease—a condition still in high need of effective treatment options. Don't miss the full discussion with Dr. Muehler about IMU-856’s future potential across gastrointestinal diseases #Gastroenterology #Celiac #CeliacDisease #IMU856 #Immunic #IMUX
📢 Data on Immunic's drug candidate in celiac disease published in 𝙏𝙝𝙚 𝙇𝙖𝙣𝙘𝙚𝙩 𝙂𝙖𝙨𝙩𝙧𝙤𝙚𝙣𝙩𝙚𝙧𝙤𝙡𝙤𝙜𝙮 & 𝙃𝙚𝙥𝙖𝙩𝙤𝙡𝙤𝙜𝙮! 📢 We are pleased to share that our phase 1 data in healthy human subjects and phase 1b data in patients with celiac disease from our clinical trial of IMU-856 has been published in this prestigious peer reviewed journal. ▶ https://bit.ly/3AFIX1wThe article around lead author, Dr. A. James Daveson, Gastroenterologist, Wesley Research Institute and Coral Sea Clinical Research Institute, Queensland, Australia provides insights into IMU-856’s phase 1 clinical profile and its potential to support gut health and restore barrier function – key challenges in celiac disease.The Lancet #Immunic #IMUX #Gastroenterology #CeliacDisease #Celiac #IMU856
📢 Join us today until November 9 at the 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝟮𝟯𝟴: 𝗜𝗺𝗺𝘂𝗻𝗼-𝗠𝗲𝗱𝗶𝗮𝘁𝗲𝗱 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗼𝗳 𝘁𝗵𝗲 𝗚𝗜 𝗧𝗿𝗮𝗰𝘁: 𝗪𝗵𝗲𝗿𝗲 𝗗𝗼 𝗪𝗲 𝗦𝘁𝗮𝗻𝗱? in Florence,🇮🇹 Italy.Sara Elhag, PhD Elhag, Ph.D., Immunic's Associate Manager Translational Pharmacology, will present a poster on the very encouraging data from our phase 1b clinical trial of IMU-856 in celiac disease. 🌾Falk Foundation #Celiac #CeliacDisease #IMU856 #Gastroenterology #IMUX #Immunic

Join now to see what you are missing

Join now

Immunic Therapeutics | LinkedIn (original) (raw)

Biotechnology Research

New York City, New York 6,994 followers

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and autoimmune diseases

About us

Locations

Employees at Immunic Therapeutics

Updates

Join now to see what you are missing

Similar pages

Browse jobs

Funding